EP3452033A4 - Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon - Google Patents

Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon Download PDF

Info

Publication number
EP3452033A4
EP3452033A4 EP17793224.1A EP17793224A EP3452033A4 EP 3452033 A4 EP3452033 A4 EP 3452033A4 EP 17793224 A EP17793224 A EP 17793224A EP 3452033 A4 EP3452033 A4 EP 3452033A4
Authority
EP
European Patent Office
Prior art keywords
fabricating
methods
ophthalmic compositions
pharmaceutical ophthalmic
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17793224.1A
Other languages
English (en)
French (fr)
Other versions
EP3452033A1 (de
Inventor
William Wiley
Richard Dilzer
Dennis Elias Saadeh
Jeffrey T. Liegner
John Scott Karolchyk
Bernard Covalesky
Kallan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow IP LLC
Original Assignee
Harrow IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/148,574 external-priority patent/US20160243031A1/en
Priority claimed from US15/178,812 external-priority patent/US20160279055A1/en
Application filed by Harrow IP LLC filed Critical Harrow IP LLC
Publication of EP3452033A1 publication Critical patent/EP3452033A1/de
Publication of EP3452033A4 publication Critical patent/EP3452033A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17793224.1A 2016-05-06 2017-05-03 Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon Withdrawn EP3452033A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/148,574 US20160243031A1 (en) 2013-07-22 2016-05-06 Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US15/178,812 US20160279055A1 (en) 2013-07-22 2016-06-10 Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
PCT/US2017/030772 WO2017192675A1 (en) 2016-05-06 2017-05-03 Pharmaceutical ophthalmic compositions and methods for fabricating thereof

Publications (2)

Publication Number Publication Date
EP3452033A1 EP3452033A1 (de) 2019-03-13
EP3452033A4 true EP3452033A4 (de) 2020-02-12

Family

ID=60203416

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17793224.1A Withdrawn EP3452033A4 (de) 2016-05-06 2017-05-03 Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon

Country Status (6)

Country Link
EP (1) EP3452033A4 (de)
JP (1) JP6694525B2 (de)
KR (2) KR20190109604A (de)
AU (1) AU2017260327B2 (de)
CA (1) CA3023243C (de)
WO (1) WO2017192675A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074326A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd. Methods and compositions for the treatment of ophthalmic conditions
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
WO2021252054A1 (en) * 2020-06-10 2021-12-16 Ocular Science, Inc. Compositions and uses in method for post-operative ocular care
EP4238552A1 (de) * 2020-10-29 2023-09-06 Taejoon Pharmaceutical Co., Ltd. Ophthalmische zusammensetzung
WO2022156371A1 (zh) * 2021-01-22 2022-07-28 成都瑞沐生物医药科技有限公司 一种眼用制剂的载体或辅料及其制备方法和应用
US12594351B2 (en) 2021-08-04 2026-04-07 Harrow Ip Llc Methods for increasing shelf-life of ophthalmic pharmaceutical compositions
WO2025259121A1 (en) * 2024-06-12 2025-12-18 Aft Pharmaceuticals Ltd Vancomycin eye drops

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150025511A1 (en) * 2013-07-22 2015-01-22 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) * 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) * 2014-08-15 2016-04-14 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
JP2003510263A (ja) * 1999-09-24 2003-03-18 アルコン,インコーポレイテッド シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
EP1596823A2 (de) * 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. Stabile ophthalmische zusammensetzung
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
BRPI0819908A2 (pt) * 2007-11-27 2015-05-19 Alcon Res Ltd Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
MX383077B (es) * 2013-07-22 2025-03-13 Novel Drug Solutions Llc Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150025511A1 (en) * 2013-07-22 2015-01-22 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) * 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) * 2014-08-15 2016-04-14 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017192675A1 *

Also Published As

Publication number Publication date
KR20190109604A (ko) 2019-09-25
JP6694525B2 (ja) 2020-05-13
WO2017192675A1 (en) 2017-11-09
CA3023243A1 (en) 2017-11-09
CA3023243C (en) 2020-01-21
AU2017260327B2 (en) 2018-12-20
JP2019514975A (ja) 2019-06-06
EP3452033A1 (de) 2019-03-13
AU2017260327A1 (en) 2018-11-29
KR20180126087A (ko) 2018-11-26

Similar Documents

Publication Publication Date Title
EP3377040B8 (de) Pharmazeutische verpackung für ophthalmische formulierungen
EP3585433A4 (de) Therapeutische zusammensetzungen und verwandte verfahren zur photoimmuntherapie
GB201913962D0 (en) Ophthalmic drug compositions
EP3442543A4 (de) Zusammensetzungen und verfahren für neurogenese
EP3357513A4 (de) Pharmazeutische zusammensetzung und verabreichung davon
EP3452033A4 (de) Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon
EP3233111A4 (de) Pharmazeutische zusammensetzung mit plasminogen und verwendungen davon
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
EP3307265A4 (de) Pharmazeutische kombination und verwendungen davon
EP3052095A4 (de) Epinephrinbasierte ophthalmische zusammensetzungen zur intraokularen verabreichung und verfahren zur herstellung davon
EP3398598A4 (de) Sulfonamidderivat und herstellungsverfahren und verwendung davon
EP3192875A4 (de) Pharmazeutische retard-zusammensetzung zur behandlung und vorbeugung von augenerkrankungen
EP3554486A4 (de) Pharmazeutische formulierungen zur behandlung von glaukom sowie verfahren zur herstellung und verwendung davon
EP3672598A4 (de) Arzneimittelzusammensetzungen für das auge
EP3185873A4 (de) Pharmazeutische zusammensetzung und verfahren
EP3227298A4 (de) Verfahren zur herstellung von baricitinib und zwischenprodukten davon
EP3107534A4 (de) Zusammensetzungen und verfahren zur behandlung von degenerativen erkrankungen
EP3424521A4 (de) Pharmazeutische zusammensetzung und herstellungsverfahren dafür
EP3512529A4 (de) Arzneimittelverabreichungszusammensetzungen und -verfahren
EP3265103A4 (de) Zusammensetzungen und verfahren zur behandlung von augenerkrankungen
EP3554508A4 (de) Pharmazeutische formulierungen von suvorexant
EP3496714A4 (de) Arzneimittelzusammensetzungen
EP3355929A4 (de) Neuartige ophthalmische zusammensetzung mit rebamipid und verfahren zur herstellung davon
EP3533448A4 (de) Stabile pharmazeutische zusammensetzung
EP3491459A4 (de) Ophthalmische vorrichtungen und zugehörige verfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HARROW HEALTH, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HARROW IP, LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20200115

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101ALI20200109BHEP

Ipc: A61K 47/10 20170101ALI20200109BHEP

Ipc: A61K 31/47 20060101ALI20200109BHEP

Ipc: A61K 31/4709 20060101ALI20200109BHEP

Ipc: A61K 47/26 20060101ALI20200109BHEP

Ipc: A61P 27/02 20060101ALI20200109BHEP

Ipc: A61K 45/06 20060101ALI20200109BHEP

Ipc: A61K 31/573 20060101ALI20200109BHEP

Ipc: A61K 47/38 20060101ALI20200109BHEP

Ipc: A61K 31/196 20060101AFI20200109BHEP

Ipc: A61K 31/496 20060101ALI20200109BHEP

Ipc: A61K 9/10 20060101ALI20200109BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012052

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210316